Check the appropriate box: | |
o | Preliminary Proxy Statement |
o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
x | Definitive Proxy Statement |
o | Definitive Additional Materials |
o | Soliciting Material under §240.14a-12 |

Payment of Filing Fee (Check all boxes that apply): | ||
x | No fee required. | |
o | Fee paid previously with preliminary materials. | |
o | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. | |

![]() | A Letter from our Executive Chairman and Chief Executive Officer |



NOTICE OF ANNUAL MEETING OF SHAREHOLDERS |
April 2, 2026 | |
By Order of the Board of Directors, | |
![]() Joy Liu Chief Legal Officer |
IMPORTANT NOTICE REGARDING INTERNET AVAILABILITY OF PROXY MATERIALS. This notice, our proxy statement, and our Annual Report on Form 10-K for the year ended December 31, 2025 are first being made available to holders of record of our common stock on or about April 2, 2026. These materials are available to holders of record of our common stock at www.envisionreports.com/VRTX and to beneficial holders of our common stock at www.edocumentview.com/VRTX. | ||
Board Structure and Composition ........................................................................................................................................................... | |
Director Criteria, Qualifications and Experience ............................................................................................................................... | |
Board Refreshment ................................................................................................................................................................................ | |
Shareholder-Recommended Director Candidates ........................................................................................................................... | |
Majority Votes Cast Standard ............................................................................................................................................................... | |
Director Nominees ...................................................................................................................................................................................... | |
Director Independence ............................................................................................................................................................................. | |
Board Leadership Structure ..................................................................................................................................................................... | |
Executive Chair of the Board .................................................................................................................................................................... | |
Lead Independent Director ...................................................................................................................................................................... | |
Board Committees ...................................................................................................................................................................................... | |
Board Attendance, Committee Meetings, and Committee Membership .......................................................................................... | |
Risk Management ....................................................................................................................................................................................... | |
Code of Conduct ........................................................................................................................................................................................ | |
Insider Trading Policy ................................................................................................................................................................................ | |
Public Policy and Engagement ................................................................................................................................................................ | |
Equity Compensation Plan Information ................................................................................................................................................... | |
Executive Summary .................................................................................................................................................................................... | |
Detailed Discussion and Analysis ........................................................................................................................................................... | |
Summary Compensation Table ................................................................................................................................................................ | |
Grants of Plan-Based Awards During 2025 ........................................................................................................................................... | |
Outstanding Equity Awards at Fiscal Year-End for 2025 .................................................................................................................... | |
Option Exercises and Stock Vested for 2025 ........................................................................................................................................ | |
Other Matters .............................................................................................................................................................................................. | |
Shareholder Proposals and Nominations for Director for the 2027 Annual Meeting ...................................................................... | |
Shareholder Communications to the Board ........................................................................................................................................... | |
Householding of Annual Meeting Materials ........................................................................................................................................... | |
Solicitation .................................................................................................................................................................................................... | |
Forward-Looking Statements .................................................................................................................................................................... | |

VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 1 |
Meeting Information |
![]() | Date and Time Wednesday, May 13, 2026 9:00 a.m. (Eastern Time) | ![]() | Location https://meetnow.global/ MMMVT4H | ![]() | Record Date Close of business on March 16, 2026 | |||||
Voting Roadmap |
Item 1: | Elect Each of the Director Nominees for One Year Term Expiring in 2027 | FOR all Nominees | page 8 |
Item 2: | Ratify Selection of Independent Auditor for 2026 | FOR | page 33 |
Item 3: | Approve, on an Advisory Basis, Our Named Executive Officer Compensation | FOR | page 36 |
Item 4: | Approve Our 2026 Stock and Option Plan | FOR | page 38 |
Item 5: | Shareholder Proposal Regarding Shareholder Right To Act By Written Consent | AGAINST | page 45 |

2 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
How to Vote |
![]() | By Internet | Vote at www.envisionreports.com/VRTX before the annual meeting. | |
![]() | By Mail | If you have received written proxy materials, by completing, signing, dating, and mailing your proxy card in the envelope provided. | |
![]() | By Telephone | Vote by following the instructions on the Notice of Internet Availability of Proxy Materials or proxy card. | |
![]() | By Attending the Annual Meeting Online | During the annual meeting, you may vote online by following the instructions at https:// meetnow.global/MMMVT4H. Have the Notice of Internet Availability of Proxy Materials, which contains your control number, available when you access the virtual meeting webpage. | |
Director Nominees |
Name, Occupation or Experience | Age | Director Since | Independent | Committees | |||
AC | MDCC | CGNC | S&T | ||||
Jeffrey Leiden Executive Chairman, Vertex | 70 | 2009 | No | ||||
Reshma Kewalramani CEO and President, Vertex | 53 | 2020 | No | ||||
Sangeeta Bhatia John J. and Dorothy Wilson Professor of Health Sciences & Technology/Electrical Engineering & Computer Science, MIT | 57 | 2015 | Yes | ![]() | ![]() | ||
Lloyd Carney Chief Executive Officer, Carney Global Ventures, LLC Former CEO, Brocade Communications | 64 | 2019 | Yes | ![]() | ![]() | ||
Alan Garber President, Harvard University | 70 | 2017 | Yes | ![]() | ![]() | ||
Michel Lagarde Former Executive Vice President and Chief Operating Officer, Thermo Fisher Scientific Inc. | 52 | 2023 | Yes | ![]() | |||
Diana McKenzie Former Chief Information Officer, Workday Former Chief Information Officer, Amgen | 61 | 2020 | Yes | ![]() | ![]() | ||
Bruce Sachs Partner Emeritus, Charles River Ventures | 66 | 1998 | Yes | ![]() | ![]() | ||
Jennifer Schneider Co-Founder and CEO, Homeward Health Inc. | 51 | 2024 | Yes | ![]() | |||
Nancy Thornberry Former CEO, Kallyope, Inc. | 69 | 2023 | Yes | ![]() | |||
Suketu Upadhyay Chief Financial Officer and Executive Vice President, Zimmer Biomet | 57 | 2022 | Yes | ![]() | ![]() | ||
= Chair ![]() | |||||||

VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 3 |



Financial Performance |






4 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Marketed Products |
Research and Development |
Pipeline |


VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 5 |
Increasing Shareholder Value |
![]() |

6 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Corporate Responsibility |
2025 Compensation Decisions and Pay-for-Performance |

VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 7 |
Shareholder Outreach and Engagement |
Corporate Governance |
Board and Committee Oversight | ![]() | Oversight of Corporate Strategy and Objectives | ||
![]() | Oversight of Risk Management | |||
Independence | ||||
![]() | 9 of 11 Director Nominees Independent | |||
![]() | All Board Committee Members Independent | |||
![]() | Lead Independent Director Presides at Executive Sessions | |||
Tenure | ||||
![]() | 9 of 11 Director Nominees with ≤10 years of Service | |||
Pay for Performance | ||||
![]() | Executive Compensation Links Pay and Performance | |||
![]() | 90% of Compensation is Performance-linked | |||
![]() | Compensation Program Aligns Detailed Goals with Overall Business Strategy | |||
Shareholder Rights | ||||
![]() | Majority Voting for Directors | |||
![]() | Proxy Access Rights for Holders of 3% for 3 years | |||
![]() | All Directors Elected Each Year | |||
Board Practices | ||||
![]() | Annual Board and Committee Self-evaluations | |||
![]() | New Director Orientation and Continuing Director Education | |||
![]() | Code of Conduct and Ethics applies to Board Members |
8 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Director Criteria, Qualifications and Experience |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 9 |
Bhatia | Carney | Garber | Kewalramani | Lagarde | Leiden | McKenzie | Sachs | Schneider | Thornberry | Upadhyay | |
Leadership Experience. We believe that directors who have held significant leadership positions over extended periods of time provide our company with special insights. | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Industry Knowledge. We seek directors with substantive knowledge of the healthcare and biotechnology industries to successfully advise and oversee the strategic development and direction of our company. | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ||
Financial Expertise. We believe that an understanding of finance is important for members of our board, and our budgeting processes and financial and strategic transactions require our directors to be financially knowledgeable. | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | |
International Perspective. We have significant operations outside the United States and value directors with experience in the operation of complex multinational organizations. | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | |||
Public Policy and Regulation. We operate in a highly-regulated industry and seek directors who have experience in public policy and the regulation of medicines. | ![]() | ![]() | ![]() | ![]() | |||||||
Academic Experience or Technological Background. As a biotechnology company that seeks to develop transformative medicines for patients with serious diseases, we look for directors with backgrounds in academia, science and technology and, in particular, the research and development of pharmaceutical products. | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ||
Commitment to Company Values and Goals. We seek directors who are committed to our company and its values and goals and who value the contributions that can be provided by individuals who believe in our company and its prospects for success. | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Independence | Y | Y | Y | N | Y | N | Y | Y | Y | Y | Y |
Age | 57 | 64 | 70 | 53 | 52 | 70 | 61 | 66 | 51 | 69 | 57 |
Tenure on Board | 10 | 7 | 8 | 6 | 2 | 16 | 6 | 27 | 2 | 2 | 4 |



10 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Board Refreshment |
Shareholder-Recommended Director Candidates |
Provision | Requirement |
Ownership Threshold and Holding Period | Available to shareholders owning 3% or more of our voting shares continuously for at least 3 years. |
Number of Board Nominees | Total number of proxy access nominees is capped at the greater of 20% of the existing number of board seats (or the closest whole number below 20%) and two. |
Aggregation Limits | 20-shareholder limit on the number of shareholders who can aggregate their shares to satisfy the 3% ownership requirement. |
Proxy Fights | Proxy access nominees will not be included in the proxy materials if we receive notice that a shareholder intends to nominate a candidate who is not to be included in our proxy materials. |
Future Ineligibility | Proxy access nominees who fail to receive at least 10% of the votes cast “for” such nominee may not be re-nominated as a proxy access nominee for the next two annual meetings. |
Majority Votes Cast Standard |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 11 |
![]() | Sangeeta Bhatia | ||
Age: 57 Director Since: 2015 | Board Committees: •Chair – Science and Technology Committee •Member – Corporate Governance and Nominating Committee | ||
Experience: | |||
Other Public Company Boards: •None | •John J. and Dorothy Wilson Professor of Health Sciences & Technology/Electrical Engineering & Computer Science at the Massachusetts Institute of Technology (“MIT”) since 2005; Director of the Marble Center for Cancer Nanomedicine at the Koch Institute for Integrative Cancer Research at MIT since 2016; Investigator of the Howard Hughes Medical Institute at MIT since 2008 •Co-Founder of Ropirio Therapeutics, a private biotechnology company focused on lymphatic medicine, since 2023 •Co-Founder of Amplifyer Bio, a private biotechnology company focused on oncology diagnostics, since 2023 •Co-Founder of Matrisome Bio, a private biotechnology company, since 2023 •Co-Founder of Port Therapeutics, a private company focused on thermal bioswitches in oncology, since 2022 •Co-Founder of Satellite Bio, a private company focused on developing satellite organs as living therapeutic solutions, since 2020 •Co-Founder of Glympse Bio, a private company focused on developing in vivo sensing technology dedicated to disease monitoring, from 2018 until it was acquired by Sunbird Bio, Inc. in August 2023 •Professor of bioengineering and medicine at the University of California at San Diego, from 1998 through 2005 •Member of the Department of Medicine at Brigham and Women’s Hospital and member of the Broad Institute •Holds a Sc.B. in biomedical engineering from Brown University, an S.M. and Ph.D. in Mechanical Engineering from MIT, and an M.D. from Harvard Medical School | ||
Key Skills and Qualifications: Dr. Bhatia is a leading academic scientist and medical researcher. Her extensive experience in the field of biomedical engineering and in-depth understanding on the use of advanced technologies in medical research provide valuable insights to our board of directors, including with respect to our key research and development initiatives. | |||
12 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
![]() | Lloyd Carney | ||
Age: 64 Director Since: 2019 | Board Committees: •Chair – Corporate Governance and Nominating Committee •Member – Audit and Finance Committee | ||
Experience: | |||
Other Public Company Boards: •Visa Inc. •Grid Dynamics Holdings Inc. | •Chief Executive Officer and Chairman, Carney Global Ventures, LLC, an early round investor, since March 2007 •Chief Acquisition Officer of Carney Technology Acquisition Corp. II, a special purpose acquisition corporation, from October 2020 until February 2023 •Chief Executive Officer of ChaSerg Technology Acquisition Corp., a technology acquisition company, from September 2018 until March 2020 •Chief Executive Officer and Director of Brocade Communications Systems Inc., a global supplier of networking hardware and software, from 2013 until it was acquired by Broadcom in 2017 •Chief Executive Officer of Xsigo Systems, a cloud-based infrastructure solutions provider, from 2008 until it was acquired by Oracle in 2012 •Chief Executive Officer and Chairman of Micromuse Inc., a software solutions provider for business and service assurance, from 2003 until it was acquired by IBM in 2006 •Previously held senior leadership roles at Juniper Networks, Inc., Nortel Networks Inc., and Bay Networks, Inc. •Member of the board of directors of Nuance Communications Inc., a publicly traded AI-enabled communication company, until it was acquired by Microsoft Corp in March 2022 •Ambassador/Special Investment Envoy for Technology Jamaica, since May 2023 •Chancellor for the University of Technology, Jamaica, a public university in Jamaica, since August 2022 •Holds a Bachelor of Science degree in Electrical Engineering Technology from Wentworth Institute of Technology, a Master of Science degree in Applied Business Management from Lesley College, an Honorary Doctorate degree in Engineering from Wentworth Institute of Technology and an Honorary Doctorate degree in Technology from University of Technology Jamaica | ||
Key Skills and Qualifications: Mr. Carney brings strong business judgment, honed through his time as a senior executive and board member of multiple global technology companies, to our board of directors. As Chief Executive Officer of multiple technology companies, Mr. Carney has extensive experience in operations, strategic planning, finance, information technology and cybersecurity, and risk management. | |||
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 13 |
![]() | Alan Garber | ||
Age: 70 Director Since: 2017 | Board Committees: •Member – Corporate Governance and Nominating Committee •Member – Science and Technology Committee | ||
Experience: | |||
Other Public Company Boards: •None | •President of Harvard University since August 2024 after serving as Interim President from January to August 2024; Provost of Harvard University and the Mallinckrodt Professor of Health Care Policy at Harvard Medical School, a Professor of Economics in the Faculty of Arts and Sciences, Professor of Public Policy in the Harvard Kennedy School of Government, and Professor in the Department of Health Policy and Management in the Harvard T.H. Chan School of Public Health, from September 2011 to August 2024 •Henry J. Kaiser Jr. Professor, a Professor of Medicine, and a Professor (by courtesy) of Economics, Health Research and Policy, and of Economics in the Graduate School of Business at Stanford University, from 1998 until 2011 •Member of the National Academy of Medicine, the American Society of Clinical Investigation, the Association of American Physicians, and the American Academy of Arts and Sciences •Member of the board of Directors of Exelixis, Inc., a genomics-based drug-discovery company, from January 2005 to May 2024 •Fellow of the American Association for the Advancement of Science, the American College of Physicians, and the Royal College of Physicians •Current Research Associate with the National Bureau of Economic Research and served for nineteen years as founding Director of its Health Care Program •Previously served as a member of the National Advisory Council on Aging at the National Institutes of Health, as a member of the Board of Health Advisers of the Congressional Budget Office, and as Chair of the Medicare Evidence Development and Coverage Advisory Committee at the Centers for Medicare and Medicaid Services •Holds an A.B. summa cum laude, an A.M. and a Ph.D., all in Economics, from Harvard University, and an M.D. with research honors from Stanford University | ||
Key Skills and Qualifications: Dr. Garber brings extensive leadership experience and knowledge regarding science, medicine, and the healthcare industry, and in particular, healthcare economics, to our board of directors. His expertise in health care policy and as an advisor to government agencies provides our board with important insights and perspectives on the issues facing our company. | |||
14 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
![]() | Reshma Kewalramani | ||
Age: 53 Director Since: 2020 | Position: •Chief Executive Officer and President | ||
Experience: | |||
Other Public Company Boards: •None | •Chief Executive Officer and President of Vertex Pharmaceuticals Incorporated since April 2020 •Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Incorporated from 2018 through March 2020 •Senior Vice President, Late Development of Vertex from 2017 until 2018 •Served in roles of increasing responsibility at Amgen Inc. from 2004 to 2017, most recently as Vice President and Head of U.S. Medical Organization •Industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee from 2014 through 2019 •Member of the Board of Directors of Ginkgo Bioworks Holdings, Inc., a publicly traded biotechnology company, from 2021 to 2024 •Holds a B.A. from Boston University and an M.D. from Boston University School of Medicine; Dr. Kewalramani completed her internship and residency in Internal Medicine at the Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Women’s Hospital combined program •Dr. Kewalramani is an alumna of the Harvard Business School, having completed the General Management Program | ||
Key Skills and Qualifications: Dr. Kewalramani possesses strong leadership qualities, significant experience overseeing and scaling the operations of a global enterprise, deep expertise in drug development, and wide-ranging experience in policy matters, demonstrated through her services as a senior executive in the biotechnology sector. She is a physician-executive with extensive industry knowledge garnered through her scientific and medical roles and experience as a global senior leader across multiple disease areas and all stages of drug development. She provides our board of directors with in-depth knowledge of our company gained during her various senior management roles within Vertex and through the day-to-day leadership of our executives as CEO. | |||
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 15 |
![]() | Michel Lagarde | ||
Age: 52 Director Since: 2023 | Board Committees: •Member – Audit and Finance Committee | ||
Experience: | |||
Other Public Company Boards: •None | •Former Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific Inc. (“Thermo Fisher”), a supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services, from January 2022 through March 2026; Thermo Fisher is a supplier to Vertex •Executive Vice President at Thermo Fisher from 2019 through 2021 •Senior Vice President and President, Pharma Services at Thermo Fisher from 2017 to 2019, joining Thermo Fisher as Senior Vice President, as a result of its acquisition of Patheon N.V., a pharma services company, in 2017 •President and Chief Operating Officer of Patheon N.V. from 2016 to 2017 •Managing Director of JLL Partners, a private equity firm focused on healthcare, from 2008 to 2016 •Holds a bachelor’s degree in business administration from European University in Antwerp and an executive master’s degree in finance and control from the University of Maastricht and University of Amsterdam | ||
Key Skills and Qualifications: Mr. Lagarde has deep experience across numerous segments of the health care industry and markets around the world, as well as a successful track record of growing and scaling profitable businesses. He brings to our board of directors strong leadership experience in biotechnology and pharmaceutical development and commercial manufacturing services, as well as financial expertise across several international markets. | |||
16 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
![]() | Jeffrey Leiden | ||
Age: 70 Director Since: 2009 | Position: •Executive Chairman | ||
Experience: | |||
Other Public Company Boards: •None | •Chief Executive Officer and President of Vertex Pharmaceuticals Incorporated from 2012 through March 2020 •Chairman of Board of Directors of Vertex Pharmaceuticals Incorporated since 2012; previously served as lead independent director from 2010 through 2011 •Managing Director at Clarus Ventures, a life sciences venture capital firm, from 2006 to 2012 •President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals Products Group and a member of the board of directors of Abbott Laboratories from 2001 to 2006 •Held several academic appointments from 1987 to 2000, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School •Elected member of both the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences •Member of the board of directors of Quest Diagnostics Incorporated, a publicly traded medical diagnostics company, from 2014 to May 2019; member of the board of directors and non-executive Vice Chairman of Shire plc, a specialty biopharmaceutical company, from 2006 to 2012; Chairman of Revolution Healthcare Acquisition Corp., a special purpose acquisition corporation, from April 2021 to December 2022 •Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago | ||
Key Skills and Qualifications: Dr. Leiden possesses strong leadership qualities, demonstrated through his service as a senior executive in the biotechnology and pharmaceutical industries and as a life sciences venture capitalist. He has extensive knowledge of the science underlying drug discovery and development through his experiences as a distinguished physician, scientist, and teacher. As our former CEO and as a former senior executive at Abbott Laboratories, he brings a global perspective to our business and public policy issues facing our company. He also provides our board of directors with in-depth knowledge of our company and our corporate strategy. | |||
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 17 |
![]() | Diana McKenzie | ||
Age: 61 Director Since: 2020 | Board Committees: •Member – Audit and Finance Committee •Member – Management Development and Compensation Committee | ||
Experience: | |||
Other Public Company Boards: •MetLife Inc. •agilon health, inc. | •Chief Information Officer of Workday, Inc., a cloud-based financial and human capital management software company, from 2016 until April 2019 •Held roles of increasing responsibility at Amgen Inc., a biotechnology company, for 12 years, most recently serving as Senior Vice President and Chief Information Officer •Held various leadership roles at Eli Lilly and Company, a pharmaceutical company, for 17 years, focused on drug development, reducing time to market, and improving technology and security standards •Member of the board of directors of Change Healthcare, Inc., a publicly traded healthcare technology company, from August 2019 until it was acquired by United Health Group in October 2022 •Holds a Bachelor of Science degree in Computer Information Systems from Purdue University and completed the Information Technology Management Program at University of California, Los Angeles and the CERT Certification for Cybersecurity Oversight from Carnegie Mellon’s Software Engineering Institute | ||
Key Skills and Qualifications: Ms. McKenzie has corporate leadership experience and industry knowledge that make her a valuable contributor to our board of directors. Her service as an executive and innovator in the biotechnology and technology industries and as a member of the board of directors of public companies involved in healthcare issues provide her with multiple perspectives on our industry. Ms. McKenzie brings extensive experience growing, scaling, and transforming global businesses in the healthcare and software industries. In addition, Ms. McKenzie is a proven technology leader who brings extensive digital, technology, and cybersecurity knowledge and perspective based on nearly three decades of experience in the space. | |||
18 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
![]() | Bruce Sachs | ||
Age: 66 Director Since: 1998 | Position: •Lead Independent Director Board Committees: •Chair – Management Development and Compensation Committee •Member – Corporate Governance and Nominating Committee | ||
Other Public Company Boards: •None | Experience: | ||
•Partner Emeritus at Charles River Ventures (“CRV”), a venture capital firm; General Partner at CRV for more than 20 years, including more than 10 years as the Managing Partner •Executive Vice President and General Manager of Ascend Communications, Inc. from 1998 to 1999 •President and Chief Executive Officer of Stratus Computer, Inc. from 1997 until it was acquired by Ascend Communications in 1998 •Executive Vice President and General Manager of the Internet Telecom Business Group at Bay Networks, Inc. from 1995 to 1997 •President and Chief Executive Officer of Xylogics, Inc. from 1993 until it was acquired by Bay Networks in 1995 •Holds a B.S.E.E. in electrical engineering from Bucknell University, an M.E.E. in electrical engineering from Cornell University, and an M.B.A. from Northeastern University | |||
Key Skills and Qualifications: Mr. Sachs brings exceptionally strong business judgment to our board, honed through his experience developing business strategy as a senior executive and in venture capital. Mr. Sachs has an incomparable understanding of our business, gained through his service on the board of directors of the Company, and of the global business environment. In addition, Mr. Sachs has significant business leadership experience, financial expertise, and knowledge with respect to information technology and security, having served as a technology company CEO and as a board member of several computer networking companies. | |||
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 19 |
![]() | Jennifer Schneider | ||
Age: 51 Director Since: 2024 | Board Committees: •Member – Management Development and Compensation Committee | ||
Experience: | |||
Other Public Company Boards: •None | •Co-Founder and Chief Executive Officer of Homeward Health Inc., a company committed to rearchitecting the delivery of health and care in rural America in partnership with communities, since 2022 •President of Livongo Health, a biotechnology company, from December 2018 to October 2020, and served as the Chief Medical Officer from September 2015 to December 2018 •Served in multiple leadership roles at Castlight Health, Inc., a healthcare navigation company, from 2010 to 2015, most recently as Chief Medical Officer •Member of the board of directors at Revolution Healthcare Acquisition Corp., a special purpose acquisition company, from March 2021 to December 2022 •Member of the board of directors at Health Assurance Acquisition Corp., a special purpose acquisition company, from September 2020 until it liquidated in November 2022 •Holds a B.S. in Biology from the College of the Holy Cross, an M.D. from Johns Hopkins School of Medicine, and an M.S. in Health Services Research from Stanford University | ||
Key Skills and Qualifications: Dr. Schneider has deep knowledge and expertise in healthcare and technology. She has led or held senior leadership roles in multiple companies focused on delivering innovative solutions in healthcare management. At Livongo, Dr. Schneider led the company through the largest consumer digital health initial public offering in history as well as its merger with Teladoc Health, the industry’s largest ever merger. Dr. Schneider brings extensive experience as a practicing physician and as a leader building healthcare companies that use technology to provide access to clinical services. | |||
![]() | Nancy Thornberry | ||
Age: 69 Director Since: 2023 | Board Committees: •Member – Science and Technology Committee | ||
Experience: | |||
Other Public Company Boards: •Denali Therapeutics •Schrödinger Inc. | •Founder and Chief Executive Officer of Kallyope, Inc. (“Kallyope”), a private biotechnology company, from November 2015 to October 2021, and served as Chair of Research and Development through December 2023 •Self-employed as a consultant to companies in the biotechnology and pharmaceutical industries from August 2013 to October 2015 •Served in roles of increasing responsibility at Merck & Co., Inc., a pharmaceutical company, for more than 30 years, most recently as Senior Vice President and Franchise Head, Diabetes and Endocrinology •Holds a B.S. in Chemistry and Biology from Muhlenberg College | ||
Key Skills and Qualifications: Ms. Thornberry has over 30 years of experience in the pharmaceutical and biotechnology industries and her scientific leadership has spanned across drug discovery, research & development, and business development. She brings to our board of directors leadership experience in critical scientific roles that drove innovation at both public and private companies. Her industry experience, scientific acumen and strategic thinking brings great value to our board of directors. | |||
20 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
![]() | Suketu Upadhyay | ||
Age: 57 Director Since: 2022 | Board Committees: •Chair – Audit and Finance Committee •Member – Management Development and Compensation Committee | ||
Experience: | |||
Other Public Company Boards: •None | •Chief Financial Officer and Executive Vice President - Finance, Operations and Supply Chain of Zimmer Biomet, a leading global innovator and manufacturer of orthopedic solutions, since July 2019 •Senior Vice President, Global Financial Operations at Bristol-Myers Squibb from 2016 to June 2019 •Executive Vice President and Chief Financial Officer of Endo International from 2013 to 2016 •Previously served as interim Chief Financial Officer and Senior Vice President of Finance, Corporate Controller and Principal Accounting Officer of Becton Dickinson, and Senior Vice President of Global Financial Planning and Analysis and Vice President and Chief Financial Officer of Becton Dickinson’s international business •Previously held a number of global finance and strategy roles across AstraZeneca and Johnson & Johnson, including Research and Development, Supply Chain, Commercial Operations and Business Development •Spent the early part of his career in public accounting with KPMG, earning his CPA designation and his CMA designation (each designation currently inactive) •Holds a Bachelor of Science in Finance from Albright College and an MBA from The Fuqua School of Business at Duke University | ||
Key Skills and Qualifications: Mr. Upadhyay has extensive experience in the health care industry in financial roles covering all major areas of a fully integrated life sciences business. His service as an executive in the pharmaceutical, hospital supply, and medical device industries provide him with multiple perspectives on our industry. His knowledge and expertise make him a valuable contributor to our board of directors and management. | |||
Board Recommendation |
For all of the above reasons, our board of directors unanimously recommends that you vote FOR each of the nominees. |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 21 |
22 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 23 |
Audit and Finance Committee |
24 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Corporate Governance and Nominating Committee |
Management Development and Compensation Committee |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 25 |
Science and Technology Committee |
Compensation Committee Interlocks and Insider Participation |
Director | Independence | Board | Audit Committee | CGNC | MDCC | S&T Committee |
Sangeeta N. Bhatia | ![]() | ![]() | ![]() | ![]() | ||
Lloyd Carney | ![]() | ![]() | ![]() | ![]() | ||
Alan Garber | ![]() | ![]() | ![]() | ![]() | ||
Reshma Kewalramani | ![]() | |||||
Michel Lagarde | ![]() | ![]() | ![]() | |||
Jeffrey M. Leiden | ![]() | |||||
Diana McKenzie | ![]() | ![]() | ![]() | ![]() | ||
Bruce I. Sachs | ![]() | ![]() | ![]() | ![]() | ||
Jennifer Schneider | ![]() | ![]() | ![]() | |||
Nancy Thornberry | ![]() | ![]() | ![]() | |||
Suketu Upadhyay | ![]() | ![]() | ![]() | ![]() | ||
2025 Meetings | 7 | 8 | 5 | 6 | 3 |
![]() | = Member |
![]() | = Chair |
![]() | = Lead Independent Director |
26 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 27 |
Board Committee | Area of Risk Oversight |
Audit and Finance Committee | •Financial, accounting, disclosure, insurance, tax, investment, credit, disclosure controls and procedures, and other risks reviewed in its oversight of the internal audit function •Cybersecurity •Internal audit •Compliance program •Periodic reviews of relevant developments in disclosure requirements |
Management Development and Compensation Committee | •Executive compensation policies, practices, and goal setting, including whether such policies, practices, and goal setting balance risk-taking and rewards in an appropriate manner, align with shareholder interests, and are consistent with best practices •Company incentive compensation plans and equity-based plans •Stock ownership guidelines for executive officers and officers |
Corporate Governance and Nominating Committee | •Corporate governance •Board organization, membership, and structure •Board and CEO succession planning •Director independence |
Science and Technology Committee | •Assessments of planned R&D programs and technology initiatives •Emerging science and technology issues and trends |
28 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 29 |
Non-Employee Director Compensation Program |
Compensation Elements | ||
Cash | ||
Annual Cash Retainer | $100,000 | |
Annual Committee Chair Retainer | Audit and Finance Committee | $30,000 |
Management Development and Compensation Committee | $25,000 | |
Corporate Governance and Nominating Committee | $25,000 | |
Science and Technology Committee | $25,000 | |
Committee Membership Retainer | Audit and Finance Committee | $15,000 |
Management Development and Compensation Committee | $12,500 | |
Corporate Governance and Nominating Committee | $10,000 | |
Science and Technology Committee | $10,000 | |
Annual Lead Independent Director Retainer | $55,000 | |
Equity | ||
Initial Equity Grant | A $400,000 value-based award in restricted stock units vesting after 12 months | |
Annual Equity Retainer | On May 1 of each year, a $400,000 value-based award, which the directors can elect to receive in the form of: •options that are fully-vested upon grant; •restricted stock units that vest on the first anniversary of the date of grant; or •a 50/50 mix of options and restricted stock units | |
30 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
2025 Director Compensation |
Director(1) | Fees Earned or Paid in Cash | Stock Awards(2) | Option Awards(2) | All Other Compensation(3) | Total | |||||
Sangeeta N. Bhatia | $135,000 | $400,364 | $— | $25,000 | $560,364 | |||||
Lloyd Carney | $140,000 | $400,364 | $— | $25,000 | $565,364 | |||||
Alan Garber | $120,000 | $200,182 | $200,065 | $25,000 | $545,247 | |||||
Michel Lagarde | $115,000 | $— | $400,130 | $25,000 | $540,130 | |||||
Diana McKenzie | $127,500 | $400,364 | $— | $25,000 | $552,864 | |||||
Bruce I. Sachs(4) | $190,000 | $— | $400,130 | $25,000 | $615,130 | |||||
Jennifer Schneider | $112,500 | $400,364 | $— | $25,000 | $537,864 | |||||
Nancy Thornberry | $110,000 | $200,182 | $200,065 | $18,000 | $528,247 | |||||
Suketu Upadhyay(4) | $142,500 | $400,364 | $— | $23,000 | $565,864 | |||||
2025 Equity Grants |
Grant | Date | Shares | Exercise Price | Grant-Date Fair Value | ||
Annual Non-Employee Director - 100% Option Grants | May 1, 2025 | 2,398 | $502.97 | $400,130 | ||
Annual Non-Employee Director - 50% Option Grants | May 1, 2025 | 1,199 | $502.97 | $200,065 | ||
Annual Non-Employee Director - 100% Restricted Stock Unit Grants | May 1, 2025 | 796 | — | $400,364 | ||
Annual Non-Employee Director - 50% Restricted Stock Unit Grants | May 1, 2025 | 398 | — | $200,182 | ||
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 31 |
Outstanding Equity |
Director | Outstanding Restricted Stock Units | Outstanding Deferred Stock Units | Outstanding Options (All Exercisable) |
Sangeeta N. Bhatia | 796 | — | — |
Lloyd Carney | 796 | — | — |
Alan Garber | 398 | — | 30,754 |
Michel Lagarde | — | — | 5,540 |
Diana McKenzie | 796 | 6,991 | — |
Bruce I. Sachs | — | 15,457 | 33,965 |
Jennifer Schneider | 796 | — | — |
Nancy Thornberry | 398 | — | 2,770 |
Suketu Upadhyay | 796 | 2,638 | — |
Non-Employee Director Stock Ownership Guidelines |
32 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
![]() | Improve the lives of people with serious diseases | We are focused on discovering, developing and producing innovative medicines so that people with serious diseases can lead better lives. We invest significantly in research and development, with the majority of operating expenses and our workforce dedicated to that purpose. Once we discover transformative medicines, we then work to ensure patients have access to our medicines. We are deeply committed to understanding the challenges and unmet needs of patients and recognize the importance of partnering with, elevating, and empowering patient communities. | |
![]() | Foster a culture of innovation, integrity and belonging | We are focused on fostering a culture of innovation, integrity and belonging. Our culture of high ethical standards and integrity is one of the key components to our success. All of our directors, officers, employees and contractors are responsible for complying with our Code of Conduct and upholding and demonstrating ethics and integrity in our work every day. We are committed to building an outstanding, committed and passionate team. This involves not only recruiting, retaining and developing the most talented employees, but also investing to make sure they feel supported, valued and free to bring their unique perspectives to the table. To promote our employees’ well- being and development, we also offer a variety of benefits and career development opportunities. |
![]() | Carefully manage our operations and environmental footprint | We are committed to operating our business in a sustainable manner and to limiting our environmental impact. In 2023, we established a new target to reduce our Scope 1 and Scope 2 absolute greenhouse gas (“GHG”) emissions. Approximately 50% of our global energy comes from renewable energy sources and we source approximately 99% renewable energy for our U.K.-based international headquarters and research facility. We also continually improve standards and incorporate industry best practices with regards to important topics such as employee health and safety as well as our supply chain. | |
![]() | Make a positive impact in the communities where we are located | We continue to support our communities through collaborations, donations, and volunteering across the world. In 2025, Vertex and the Vertex Foundation contributed approximately $51 million in charitable giving. The Vertex Foundation, a 501(c)(3) nonprofit organization, seeks to improve the lives of people with serious diseases and contribute to the communities where we live and work through education, innovation and health. In 2025, it supported 2,775 nonprofit organizations through the Vertex Foundation Matching Gift program. For our 17th annual Week of Service, a record 83% of employees volunteered in their local communities across more than 200 global opportunities. | |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 33 |
Service | 2025 | 2024 | ||
Audit fees | $5,649,560 | $6,192,000 | ||
Audit-related fees | — | — | ||
Tax fees | 1,405,000 | 1,326,000 | ||
All other fees | 127,200 | 7,000 | ||
TOTAL | $7,181,760 | $7,525,000 | ||
34 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Our board of directors unanimously recommends that you vote FOR ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026. |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 35 |
36 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 37 |
Our board of directors unanimously recommends that you vote FOR the approval of the resolution set forth above. |
38 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
2022 | 2023 | 2024 | 2025 | % Change 2022 to 2025 | |
(in thousands, except percentages and employee numbers) | |||||
Total Shares Granted Subject to Equity Awards | 2,338 | 2,171 | 1,865 | 1,957 | (16.3)% |
Gross Burn Rate(1) | 0.9% | 0.8% | 0.7% | 0.8% | |
Awards Cancelled, Forfeited or Expired | 311 | 245 | 203 | 249 | |
Net Dilution | 2,027 | 1,926 | 1,662 | 1,708 | (15.7)% |
Net Burn Rate | 0.8% | 0.7% | 0.6% | 0.7% | |
Average Employees During Fiscal Year(2) | 4,280 | 5,004 | 5,756 | 6,272 | |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 39 |
40 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 41 |
42 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 43 |
Name and Position | Number of Stock Options | Number of Restricted Stock Units (excluding Performance- Based Restricted Stock Units) | Number of Performance- Based Restricted Stock Units (assuming target performance) |
Reshma Kewalramani, Chief Executive Officer and President | — | 19,015 | 19,016 |
Charles F. Wagner, Jr., Executive Vice President, Chief Operating and Financial Officer (1) | — | 6,655 | 6,656 |
Carmen Bozic, Executive Vice President, Chief Medical Officer | — | 5,546 | 5,546 |
Amit Sachdev, Executive Vice President, Chief Patient and External Affairs Officer | — | 6,211 | 6,212 |
Nia Tatsis, Executive Vice President, Chief Regulatory and Quality Officer | — | 6,211 | 6,212 |
Stuart A. Arbuckle, Former Executive Vice President, Chief Operating Officer (through July 1, 2025) (2) | — | 7,903 | 7,904 |
All executive officers as of December 31, 2025, as a group | — | 62,938 | 70,153 |
All current directors who are not executive officers, as a group | 7,194 | 5,434 | — |
All employees who are not executive officers, as a group | — | 1,400,747 | 410,365 |
Our board of directors unanimously recommends that you vote FOR the approval of the 2026 Stock and Option Plan. |
44 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Plan Category | Number of Securities to be Issued Upon Exercise of Outstanding Options, Restricted Stock Units and Rights | Weighted-Average Exercise Price of Outstanding Options and Rights | Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in first column) |
Equity Compensation Plans Approved by Shareholders (1) | 4,428,350 (2) | $170.54 (3) | 11,837,576 (4) |
Equity Compensation Plans Not Approved by Shareholders | — | — | — |
TOTAL | 4,428,350 | 11,837,576 |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 45 |

46 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 47 |
48 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
For all of the above reasons, our board of directors unanimously recommends that you vote AGAINST this shareholder proposal. |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 49 |
50 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Name | Position |
Reshma Kewalramani | Chief Executive Officer and President |
Charles F. Wagner, Jr. | Executive Vice President, Chief Operating and Financial Officer(1) |
Carmen Bozic | Executive Vice President, Chief Medical Officer |
Amit Sachdev | Executive Vice President, Chief Patient and External Affairs Officer |
Nia Tatsis | Executive Vice President, Chief Regulatory and Quality Officer |
Stuart A. Arbuckle | Former Executive Vice President, Chief Operating Officer (through July 1, 2025)(2) |
Financial Performance |





VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 51 |
Marketed Products |
Research and Development |
52 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Pipeline |

VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 53 |
Increasing Shareholder Value |
![]() |
2025 Compensation Decisions and Pay-for-Performance |
54 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Shareholder Outreach and Engagement |
Compensation Governance Practices |
What We Do | ||
![]() | Caps on incentive awards | |
![]() | Multiple performance metrics | |
![]() | Range of awards; not all or nothing | |
![]() | Compensation recoupment (clawback) policy | |
![]() | Balance of short- and long-term incentives (through annual cash bonuses and equity awards) | |
![]() | Executive and Non-Employee Director Stock Ownership Guidelines | |
![]() | Independent compensation consultant | |
![]() | Annual risk review | |
![]() | Pay-for-performance sensitivity and emphasis | |
![]() | Robust shareholder outreach | |
What We Don’t Do | ||
û | Excessive executive perquisites | |
û | Supplemental pension benefits for executives | |
û | Single-trigger vesting in connection with a change-in-control for equity awards | |
û | Hedging or pledging or speculative transactions in our securities by directors and executive officers | |
û | Re-pricing of stock options without shareholder approval | |
û | Allow payment of dividends on unvested performance shares or units | |
û | 280G gross-ups (payments to offset excise taxes) in existing agreements | |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 55 |
Compensation Philosophy |
Compensation Decision-Making Process |
56 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Factor Considered | What We Look For |
Similar industry | Biotechnology or pharmaceutical industry |
Importance of medicines to patients and society | Transformative medicines for serious diseases; therapeutics for unmet needs |
Recognized focus on innovation | Breakthrough Therapy designations, priority review and/or other markers indicating unmet need |
Global operations | Significant operations both within and outside the U.S. |
Commercial operations | Marketing and selling approved medicines |
Significant R&D investment | Greater than $2.2B or 25% of revenue |
Number of employees | Greater than 2,000 employees |
Market capitalization and significance to broader economy | Market cap at least ¼ our size and/or inclusion in S&P 500 or Nasdaq 100 |
Labor market competitor | Companies we compete with for executive talent |
Companies that use Vertex as a peer | Inclusion of Vertex in proxy reported peer group |
2025 Peer Group | |
AbbVie Inc. | Eli Lilly and Company |
Alnylam Pharmaceuticals | Gilead Sciences, Inc. |
Amgen, Inc. | Incyte Corporation |
Biogen, Inc. | Jazz Pharmaceuticals plc |
BioMarin Pharmaceuticals, Inc. | Moderna, Inc. |
Bristol-Myers Squibb Company | Regeneron Pharmaceuticals, Inc. |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 57 |
Company Information | R&D Expense(1) | Operational Focus | Innovative and Importance of Medicines | Uses Vertex as Peer | Market Position | |||||||||
Orphan/ Unmet Clinical Need | Approvals: Breakthrough Therapy and Regenerative Medicine Advanced Therapies(2) | Approvals (Last 15 Years): Innovative Drugs and Regenerative Medicine Therapies(3) | ||||||||||||
Company | Industry | $ (millions) | % of Revenue | Global | Commercial | Nasdaq 100 | S&P 500 | |||||||
AbbVie | Biotech | $14,112 | 23% | ![]() | ![]() | ![]() | 8 | 10 | ![]() | |||||
Alnylam | Biotech | $1,320 | 36% | ![]() | ![]() | ![]() | 3 | 2 | ![]() | ![]() | ||||
Amgen | Biotech | $7,272 | 20% | ![]() | ![]() | ![]() | 4 | 10 | ![]() | ![]() | ![]() | |||
Biogen | Biotech | $2,294 | 23% | ![]() | ![]() | ![]() | 1 | 9 | ![]() | ![]() | ||||
BioMarin | Biotech | $929 | 29% | ![]() | ![]() | ![]() | 2 | 5 | ![]() | |||||
Bristol-Myers | Pharma | $13,672 | 28% | ![]() | ![]() | ![]() | 16 | 17 | ![]() | |||||
Eli Lilly | Pharma | $16,247 | 25% | ![]() | ![]() | ![]() | 6 | 15 | ![]() | |||||
Gilead | Biotech | $7,413 | 25% | ![]() | ![]() | ![]() | 6 | 10 | ![]() | ![]() | ![]() | |||
Incyte | Biotech | $2,066 | 40% | ![]() | ![]() | ![]() | 2 | 6 | ![]() | |||||
Jazz | Pharma | $2,385 | 56% | ![]() | ![]() | ![]() | 1 | 6 | ![]() | |||||
Moderna | Biotech | $3,132 | 161% | ![]() | ![]() | ![]() | — | 1 | ![]() | ![]() | ||||
Regeneron | Biotech | $6,123 | 43% | ![]() | ![]() | ![]() | 9 | 9 | ![]() | ![]() | ![]() | |||
Vertex | Biotech | $4,043 | 34% | ![]() | ![]() | ![]() | 10 | 8 | ![]() | ![]() | ||||
58 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Life Science Companies | |
Baxter International Inc. | Jazz Pharmaceuticals plc* |
DexCom, Inc. | Thermo Fisher Scientific Inc. |
HCA Healthcare, Inc. | United Therapeutics Corp. |
Hologic, Inc. | |
Elements of Annual Compensation |














VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 59 |
Compensation Element | Performance Link |
Annual Cash Bonus | •Annual bonus dependent on both company and individual performance factors |
Equity Awards | •Grant date value of equity awards based on target award values varies by level with differentiation for individual performance •Value of shares granted based on target set by the MDCC, adjusted for individual performance ranging from 0% for below target individual performance, 100% at target individual performance, and up to 150% for above target individual performance |
PSU Awards | •50% of PSUs with a range of shares earned from 0% to 200% of target based on one-year financial metrics (to the extent earned, vesting in equal installments over a three-year period) •50% of PSUs with a range of shares earned from 0% to 200% of target based on three-year non-financial metrics (to the extent earned, cliff-vesting after three years) |
Time-Based RSUs | •Value of awards increases or decreases based on stock price over the three-year vesting period •We consider our time-vesting RSU awards to be performance-based awards because the target number of RSUs awarded may be adjusted based on the corresponding executive’s individual performance for the relevant performance period prior to grant as well as the resulting value dependent upon increases or decreases in our stock price over the three-year vesting period |
60 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Base Salary |
Name | 2025 Base Salary | 2024 Base Salary | Increase | |||
Reshma Kewalramani | $1,600,000 | $1,600,000 | —% | |||
Charles F. Wagner, Jr. | $1,000,000 | $950,000 | 5.3% | |||
Carmen Bozic | $835,000 | $835,000 | —% | |||
Amit Sachdev | $700,000 | $700,000 | —% | |||
Nia Tatsis | $750,000 | $750,000 | —% | |||
Company and Individual Ratings |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 61 |
Goal(s) | Maximum Score | Actual 2025 Performance Score | |
Marketed Products and Late-Stage Clinical Programs | 55 | 46 | |
•Achieve CF revenue goals through compliant marketing practices, including U.S. and ex-U.S. revenue goals •Achieve CASGEVY revenue and commercialization goals through compliant marketing practices, including U.S. and ex-U.S. revenue goals •Achieve JOURNAVX revenue and commercialization goals through compliant marketing practices •Meet launch preparation objectives to support emerging franchises | |||
Pipeline Growth | 52 | 42.5 | |
•Obtain approval for ALYFTREK in younger pediatric populations ex-U.S. •Deliver proof-of-concept results in CF and non-CF clinical development programs •Advance multiple non-CF clinical development programs •Advance multiple research programs, including CF and non-CF programs | |||
Manufacturing, Innovation, Quality & Operations | 15 | 10.5 | |
•Ensure continued and uninterrupted supply of approved therapies with an appropriately diversified supply chain •Ensure resilient JOURNAVX supply chain •Scale capabilities for cell and gene therapies and biologics to support potential launches and sustain growing commercial business •Advance manufacturing plans and capabilities for pipeline products | |||
Organizational Development and Capability | 13 | 13 | |
•Execute key organizational design to support growth and scale •Advance capital projects •Continue to enhance risk management efforts •Continue to advance data and technology strategy •Continue outreach and communications to advance business and policy objectives | |||
Financial Strength | 15 | 15 | |
•Continue to manage our financial resources and to achieve financial targets | |||
3.75 | |||
TOTAL (FINAL SCORING ROUNDED TO WHOLE NUMBER) | 150 | 131 | |
62 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 63 |
64 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
RESULTS EVALUATION | |||||
Not Building | Building | Strong | Leading | ||
VALUES AND BEHAVIORS EVALUATION | Exemplary Demonstration | Not Possible | Strong | Leading | Leading Exemplary |
Living the Values | Not Building | Building | Strong | Leading | |
Inconsistent Demonstration | Not Building | Not Building | Building | Not Possible | |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 65 |
Reshma Kewalramani | 2025 Rating: | Leading |
CEO and President | 2025 Salary: | $1,600,000 |
2025 Bonus: | $4,118,640 | |
LTI Equity Grants (Feb 2026): | $16,965,000 |
66 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Charles F. Wagner, Jr. | 2025 Rating: | Leading Exemplary |
EVP, Chief Operating and Financial Officer | 2025 Salary: | $1,000,000 |
2025 Bonus: | $1,965,000 | |
LTI Equity Grants (Feb 2026): | $7,875,000 |
Carmen Bozic | 2025 Rating: | Leading |
EVP, Chief Medical Officer | 2025 Salary: | $835,000 |
2025 Bonus: | $1,378,251 | |
LTI Equity Grants (Feb 2026): | $5,850,000 |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 67 |
Amit Sachdev | 2025 Rating: | Leading Exemplary |
EVP, Chief Patient and External Affairs Officer | 2025 Salary: | $700,000 |
2025 Bonus: | $1,155,420 | |
LTI Equity Grants (Feb 2026): | $6,300,000 |
Ourania “Nia” Tatsis | 2025 Rating: | Leading Exemplary |
EVP, Chief Regulatory and Quality Officer | 2025 Salary: | $750,000 |
2025 Bonus: | $1,282,163 | |
LTI Equity Grants (Feb 2026): | $6,300,000 |
68 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Annual Cash Bonus |
Target Cash Bonus | x | Performance Factors | = | Cash Bonus | ||||
Base Salary | × | Individual Incentive Target (expressed as a percentage of base salary) | × | Company Performance Factor (expressed as a percentage of the target bonus) | × | Individual Performance Factor (expressed as a percentage of the target bonus) | = | Annual Cash Bonus Award |
90%-150% based on role | 0%-150% | 0-150% | ||||||
Individual Rating | Individual Performance Factor |
Not Building | 0% |
Building | 50%-80% |
Strong | 80%-120% |
Leading | 120%-150% |
Leading/Exemplary | 140%-150% |
Name | 2025 Base Salary | Individual Incentive Target | 2025 Target Bonus | Company Performance Factor | Individual Performance Factor | 2025 Performance Cash Bonus | ||||||||
Reshma Kewalramani | $1,600,000 | x | 150% | = | $2,400,000 | x | 131% | x | 131% | = | $4,118,640 | |||
Charles F. Wagner, Jr. | $1,000,000 | x | 100% | = | $1,000,000 | x | 131% | x | 150% | = | $1,965,000 | |||
Carmen Bozic | $835,000 | x | 90% | = | $751,500 | x | 131% | x | 140% | = | $1,378,251 | |||
Amit Sachdev | $700,000 | x | 90% | = | $630,000 | x | 131% | x | 140% | = | $1,155,420 | |||
Nia Tatsis | $750,000 | x | 90% | = | $675,000 | x | 131% | x | 145% | = | $1,282,163 | |||
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 69 |
Annual Equity Awards |
Target value | Performance Rating-Based Equity Modifiers | |||||
Not Building | Building | Strong | Leading | Leading Exemplary | ||
CEO | $13,500,000 | —% | 50% - 86.5% | 86.5% - 113.5% | 100% - 127% | 113.5% - 127% |
COO | $4,750,000 | —% | 50% - 80% | 80% - 120% | 100% - 150% | 120% - 150% |
EVP (excluding the COO) | $4,000,000 | —% | 50% - 80% | 80% - 120% | 100% - 150% | 120% - 150% |
Name | Individual Performance Rating | Performance Rating-Based Equity Modifier | Performance- Based RSU | Time-based RSU | Total Equity Value | |||||
Reshma Kewalramani | Leading | 117% | $9,067,500 | (53.4%) | $7,897,500 | (46.6%) | $16,965,000 | |||
Charles F. Wagner, Jr. | Leading Exemplary | 150% | $4,312,500 | (54.8%) | $3,562,500 | (45.2%) | $7,875,000 | |||
Carmen Bozic | Leading | 130% | $3,250,000 | (55.6%) | $2,600,000 | (44.4%) | $5,850,000 | |||
Amit Sachdev | Leading Exemplary | 140% | $3,500,000 | (55.6%) | $2,800,000 | (44.4%) | $6,300,000 | |||
Nia Tatsis | Leading Exemplary | 140% | $3,500,000 | (55.6%) | $2,800,000 | (44.4%) | $6,300,000 | |||
70 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Award Year | Company Goal | Below Threshold | Threshold | Target | Max | Results | |||||
0% Payout | 50% Payout | 100% Payout | 200% Payout | Product Revenue | Payout | ||||||
2025 | 2025 Net Product Revenues(1) | <$11.630 billion | $11.630 billion | $11.780 to $11.880 billion | >$12.030 billion | $11.91 billion | 125% | ||||
Payout | |||
2023 | CF Portfolio Milestone - initiate a proof-of-concept study for a best-in-class combination CFTR modulator therapy or for VX-522 | Achieved | 200% |
Deliver at least two completed proof-of-concept studies in non-CF programs, at least one of which has positive results | Achieved | ||
Complete enrollment in a pivotal program | Achieved |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 71 |
Other Compensation Arrangements |
72 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 73 |
Compensation Practices |
Employee | Minimum Shareholding Requirement |
CEO | 6X base salary |
EVPs | 4X base salary |
74 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 75 |
76 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Name and Principal Position | Year | Salary | Bonus | Stock Awards (1) | Non-Equity Incentive Plan Compensation | All Other Compensation | Total | ||||||
Reshma Kewalramani | 2025 | $1,600,000 | $— | $15,002,270 | $4,118,640 | $423,351 | $21,144,261 | ||||||
CEO and President | 2024 | $1,541,154 | $— | $15,002,202 | $4,941,600 | $53,712 | $21,538,668 | ||||||
2023 | $1,500,000 | $— | $15,001,894 | $4,050,000 | $42,547 | $20,594,441 | |||||||
Charles F. Wagner, Jr. | 2025 | $974,808 | $— | $5,250,817 | $1,965,000 | $51,184 | $8,241,809 | ||||||
EVP & Chief Operating and Financial Officer | 2024 | $876,443 | $— | $5,250,328 | $1,821,150 | $51,519 | $7,999,440 | ||||||
2023 | $825,000 | $— | $5,250,552 | $1,256,063 | $40,136 | $7,371,751 | |||||||
Carmen Bozic | 2025 | $835,000 | $— | $4,375,531 | $1,378,251 | $57,539 | $6,646,321 | ||||||
EVP & Chief Medical Officer | |||||||||||||
Amit Sachdev | 2025 | $700,000 | $— | $4,900,522 | $1,155,420 | $21,301 | $6,777,243 | ||||||
EVP & Chief Patient and External Affairs Officer | |||||||||||||
Nia Tatsis | 2025 | $750,000 | $— | $4,900,522 | $1,282,163 | $42,235 | $6,974,920 | ||||||
EVP & Chief Regulatory and Quality Officer | 2024 | $691,154 | $— | $5,250,328 | $1,341,900 | $50,934 | $7,334,316 | ||||||
Stuart A. Arbuckle (2) | 2025 | $521,486 | $— | $9,341,927 | $— | $132,934 | $9,996,347 | ||||||
Former EVP & Chief Operating Officer | 2024 | $941,154 | $— | $6,234,857 | $2,130,000 | $77,452 | $9,383,463 | ||||||
2023 | $900,000 | $— | $6,234,712 | $1,822,500 | $41,737 | $8,998,949 | |||||||
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 77 |
Name | 2025 | 2024 | 2023 | ||||
Reshma Kewalramani | $25,718,499 | $25,718,361 | $25,717,533 | ||||
Charles F. Wagner, Jr. | $9,001,723 | $9,000,561 | $9,000,945 | ||||
Carmen Bozic | $7,500,909 | N/A | N/A | ||||
Amit Sachdev | $8,401,217 | N/A | N/A | ||||
Nia Tatsis | $8,401,217 | $9,000,561 | N/A | ||||
Stuart A. Arbuckle | $10,689,630 | $10,688,325 | $10,688,305 | ||||
Name(1) | Base Salary | Individual Incentive Target | 2025 Target Bonus | Company Performance Factor | Individual Performance Factor | 2025 Performance Cash Bonus | ||||||||
Reshma Kewalramani | $1,600,000 | x | 150% | = | $2,400,000 | x | 131% | x | 131% | = | $4,118,640 | |||
Charles F. Wagner, Jr. | $1,000,000 | x | 100% | = | $1,000,000 | x | 131% | x | 150% | = | $1,965,000 | |||
Carmen Bozic | $835,000 | x | 90% | = | $751,500 | x | 131% | x | 140% | = | $1,378,251 | |||
Amit Sachdev | $700,000 | x | 90% | = | $630,000 | x | 131% | x | 140% | = | $1,155,420 | |||
Nia Tatsis | $750,000 | x | 90% | = | $675,000 | x | 131% | x | 145% | = | $1,282,163 | |||
Name | 401(k) Match | Life Insurance Premiums | Matching Gift Program | Other | Total | |||||
Reshma Kewalramani | $15,750 | $2,867 | $23,336 | $381,398 | (1) | $423,351 | ||||
Charles F. Wagner, Jr. | $15,750 | $1,989 | $25,000 | $8,445 | (2) | $51,184 | ||||
Carmen Bozic | $15,750 | $1,834 | $25,000 | $14,955 | (3) | $57,539 | ||||
Amit Sachdev | $15,750 | $1,652 | $— | $3,899 | (4) | $21,301 | ||||
Nia Tatsis | $5,192 | $1,719 | $20,000 | $15,324 | (5) | $42,235 | ||||
Stuart A. Arbuckle | $15,750 | $1,200 | $— | $115,984 | (6) | $132,934 | ||||
78 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Estimated Possible Payouts Under Non-Equity Incentive Plan Awards | Estimated Future Payouts Under Equity Incentive Plan Awards (shares) | All Other Stock Awards: Number of Shares of Stock or Units (#) | Grant-Date Fair Value of Stock and Option Awards ($) | ||||||||||||
Name | Grant Date | Threshold ($) | Target ($) | Maximum ($) | Threshold (#) | Target (#) | Maximum (#) | ||||||||
Reshma Kewalramani | (1) | $— | $2,400,000 | $5,400,000 | |||||||||||
(2a) | 2/12/2025 | — | 9,508 | 19,016 | $4,286,492 | ||||||||||
(2b) | 2/12/2025 | — | 9,508 | 19,016 | $2,143,246 | ||||||||||
(3) | 2/12/2025 | 19,015 | $8,572,532 | ||||||||||||
Charles F. Wagner, Jr. | (1) | $— | $1,000,000 | $2,250,000 | |||||||||||
(2a) | 2/12/2025 | — | 3,328 | 6,656 | $1,500,362 | ||||||||||
(2b) | 2/12/2025 | — | 3,328 | 6,656 | $750,181 | ||||||||||
(3) | 2/12/2025 | 6,655 | $3,000,274 | ||||||||||||
Carmen Bozic | (1) | $— | $751,500 | $1,690,875 | |||||||||||
(2a) | 2/12/2025 | — | 2,773 | 5,546 | $1,250,152 | ||||||||||
(2b) | 2/12/2025 | — | 2,773 | 5,546 | $625,076 | ||||||||||
(3) | 2/12/2025 | 5,546 | $2,500,303 | ||||||||||||
Amit Sachdev | (1) | $— | $630,000 | $1,417,500 | |||||||||||
(2a) | 2/12/2025 | 3,106 | 6,212 | $1,400,278 | |||||||||||
(2b) | 2/12/2025 | 3,106 | 6,212 | $700,139 | |||||||||||
(3) | 2/12/2025 | 6,211 | $2,800,105 | ||||||||||||
Nia Tatsis | (1) | $— | $675,000 | $1,518,750 | |||||||||||
(2a) | 2/12/2025 | — | 3,106 | 6,212 | $1,400,278 | ||||||||||
(2b) | 2/12/2025 | — | 3,106 | 6,212 | $700,139 | ||||||||||
(3) | 2/12/2025 | 6,211 | $2,800,105 | ||||||||||||
Stuart A. Arbuckle | (1) | $— | $— | $— | |||||||||||
(2a) | 2/12/2025 | — | 3,952 | 7,904 | $1,781,680 | ||||||||||
(2b) | 2/12/2025 | — | 3,952 | 7,904 | $890,840 | ||||||||||
(3) | 2/12/2025 | 7,903 | $3,562,909 | ||||||||||||
(4) | $3,106,498 | ||||||||||||||
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 79 |
Option Awards | Stock Awards | ||||||||||||
Name | Number of Securities Underlying Unexercised Options Exercisable (shares) | Number of Securities Underlying Unexercised Options Unexercisable (shares) | Option Exercise Price (per share) | Option Expiration Date (1) | Number of Shares or Units of Stock That Have Not Vested (shares) | Market Value of Shares or Units of Stock That Have Not Vested | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (shares) | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested | |||||
Reshma Kewalramani | Time-based RSU | ||||||||||||
8,991 | (2) | $4,076,160 | |||||||||||
13,552 | (3) | $6,143,935 | |||||||||||
19,015 | (4) | $8,620,640 | |||||||||||
Performance- based RSU | |||||||||||||
8,992 | (5) | $4,076,613 | |||||||||||
13,552 | (6) | $6,143,935 | |||||||||||
26,972 | (7) | $12,228,026 | |||||||||||
11,885 | (8) | $5,388,184 | |||||||||||
20,328 | (9) | $9,215,902 | |||||||||||
19,016 | (10) | $8,621,094 | |||||||||||
Charles F. Wagner, Jr. | Time-based RSU | ||||||||||||
3,147 | (2) | $1,426,724 | |||||||||||
4,743 | (3) | $2,150,286 | |||||||||||
6,655 | (4) | $3,017,111 | |||||||||||
Performance- based RSU | |||||||||||||
3,148 | (5) | $1,427,177 | |||||||||||
4,744 | (6) | $2,150,740 | |||||||||||
9,440 | (7) | $4,279,718 | |||||||||||
4,160 | (8) | $1,885,978 | |||||||||||
7,114 | (9) | $3,225,203 | |||||||||||
6,656 | (10) | $3,017,564 | |||||||||||
Stock Options | |||||||||||||
9,532 | 0 | $189.38 | 4/9/2029 | ||||||||||
Carmen Bozic | Time-based RSU | ||||||||||||
2,622 | (2) | $1,188,710 | |||||||||||
3,952 | (3) | $1,791,679 | |||||||||||
5,546 | (4) | $2,514,335 | |||||||||||
Performance- based RSU | |||||||||||||
2,622 | (5) | $1,188,710 | |||||||||||
3,952 | (6) | $1,791,679 | |||||||||||
7,866 | (7) | $3,566,130 | |||||||||||
3,466 | (8) | $1,571,346 | |||||||||||
5,928 | (9) | $2,687,518 | |||||||||||
5,546 | (10) | $2,514,335 | |||||||||||
Stock Options | |||||||||||||
5,429 | 0 | $166.96 | 5/19/2029 | ||||||||||
80 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Option Awards | Stock Awards | ||||||||||||
Name | Number of Securities Underlying Unexercised Options Exercisable (shares) | Number of Securities Underlying Unexercised Options Unexercisable (shares) | Option Exercise Price (per share) | Option Expiration Date (1) | Number of Shares or Units of Stock That Have Not Vested (shares) | Market Value of Shares or Units of Stock That Have Not Vested | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (shares) | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested | |||||
Amit Sachdev | Time-based RSU | ||||||||||||
2,622 | (2) | $1,188,710 | |||||||||||
4,743 | (3) | $2,150,286 | |||||||||||
6,211 | (4) | $2,815,819 | |||||||||||
Performance- based RSU | |||||||||||||
2,622 | (5) | $1,188,710 | |||||||||||
4,744 | (6) | $2,150,740 | |||||||||||
7,866 | (7) | $3,566,130 | |||||||||||
3,883 | (8) | $1,760,397 | |||||||||||
7,114 | (9) | $3,225,203 | |||||||||||
6,212 | (10) | $2,816,272 | |||||||||||
Stock Options | |||||||||||||
23,479 | 0 | $155.57 | 2/5/2028 | ||||||||||
25,026 | 0 | $187.53 | 2/5/2029 | ||||||||||
Nia Tatsis | Time-based RSU | ||||||||||||
2,622 | (2) | $1,188,710 | |||||||||||
4,743 | (3) | $2,150,286 | |||||||||||
6,211 | (4) | $2,815,819 | |||||||||||
Performance- based RSU | |||||||||||||
2,622 | (5) | $1,188,710 | |||||||||||
4,744 | (6) | $2,150,740 | |||||||||||
7,866 | (7) | $3,566,130 | |||||||||||
3,883 | (8) | $1,760,397 | |||||||||||
7,114 | (9) | $3,225,203 | |||||||||||
6,212 | (10) | $2,816,272 | |||||||||||
Stock Options | |||||||||||||
2,854 | 0 | $155.57 | 2/5/2028 | ||||||||||
6,145 | 0 | $187.53 | 2/5/2029 | ||||||||||
Stuart A. Arbuckle | Performance- based RSU | ||||||||||||
11,210 | (7) | $5,082,166 | |||||||||||
4,940 | (8) | $2,239,598 | |||||||||||
8,448 | (9) | $3,829,985 | |||||||||||
7,904 | (10) | $3,583,357 | |||||||||||
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 81 |
Stock Awards | ||||
Name | Number of Shares Acquired on Vesting | Value Realized on Vesting | ||
Reshma Kewalramani | 80,062 | $38,041,810 | ||
Charles F. Wagner, Jr. | 28,139 | $13,371,105 | ||
Carmen Bozic | 26,301 | $12,514,524 | ||
Amit Sachdev | 23,670 | $11,234,907 | ||
Nia Tatsis | 27,090 | $12,880,194 | ||
Stuart A. Arbuckle | 114,496 | $52,508,597 | ||
82 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Voluntary Termination or Retirement/ Termination for Cause | Separate From a Change of Control, Involuntary Termination Other Than for Cause/ Termination by Executive for Good Reason | In Connection With a Change of Control, Involuntary Termination Other Than for Cause/ Termination by Executive for Good Reason | Disability | Death | |||||
Reshma Kewalramani | |||||||||
Cash Severance Benefits | $— | $10,400,000 | $14,360,000 | $2,400,000 | $2,400,000 | ||||
Continuation of Employee Benefits | — | 57,133 | 57,133 | — | — | ||||
Accelerated Vesting of Restricted Stock Units | — | 24,720,814 | 48,404,340 | 48,404,340 | 48,404,340 | ||||
TOTAL | $— | $35,177,947 | $62,821,473 | $50,804,340 | $50,804,340 | ||||
Charles F. Wagner, Jr. | |||||||||
Cash Severance Benefits | $— | $2,000,000 | $3,000,000 | $1,000,000 | $1,000,000 | ||||
Continuation of Employee Benefits | — | 34,352 | 34,352 | — | — | ||||
Accelerated Vesting of Restricted Stock Units | — | — | 16,942,063 | 16,942,063 | 16,942,063 | ||||
TOTAL | $— | $2,034,352 | $19,976,415 | $17,942,063 | $17,942,063 | ||||
Carmen Bozic | |||||||||
Cash Severance Benefits | $— | $1,586,500 | $2,338,000 | $— | $— | ||||
Continuation of Employee Benefits | — | 38,089 | 38,089 | — | — | ||||
Accelerated Vesting of Restricted Stock Units | — | — | 14,116,270 | 14,116,270 | 14,116,270 | ||||
TOTAL | $— | $1,624,589 | $16,492,359 | $14,116,270 | $14,116,270 | ||||
Amit Sachdev | |||||||||
Cash Severance Benefits | $— | $1,330,000 | $1,960,000 | $— | $— | ||||
Continuation of Employee Benefits | — | 38,089 | 38,089 | — | — | ||||
Accelerated Vesting of Restricted Stock Units | — | 12,889,478 | 15,706,204 | 15,706,204 | 15,706,204 | ||||
TOTAL | $— | $14,257,567 | $17,704,293 | $15,706,204 | $15,706,204 | ||||
Nia Tatsis | |||||||||
Cash Severance Benefits | $— | $1,425,000 | $2,100,000 | $— | $— | ||||
Continuation of Employee Benefits | — | 23,102 | 23,102 | — | — | ||||
Accelerated Vesting of Restricted Stock Units | — | — | 15,706,204 | 15,706,204 | 15,706,204 | ||||
TOTAL | $— | $1,448,102 | $17,829,306 | $15,706,204 | $15,706,204 | ||||
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 83 |
84 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Severance Payment: | A) | 200% of the sum of her (i) base salary at the time of termination and (ii) target bonus for the year in which her employment is terminated |
B) | Any annual bonus for the year prior to the year in which the termination occurs, if not yet paid | |
C) | A pro-rated bonus for the year in which the termination occurs based on her target bonus for the year in which the termination occurs | |
Equity: | Outstanding options and RSUs unvested on the termination date would receive partial vesting based on the portion of the award(s) that would have vested during the 12-month period following the termination date. | |
Employee Benefits: | Continuation of certain employee benefits for up to 18 months | |
Severance Payment: | A) | 299% of the sum of her (i) base salary at the time of termination and (ii) target bonus for the year in which her employment is terminated |
B) | A pro-rated bonus for the year in which the termination occurs | |
C) | All cash incentive awards earned by Dr. Kewalramani, if not yet paid | |
Equity: | Full vesting of all outstanding options and restricted stock unit awards (using target or earned shares, as applicable, for performance-based awards) | |
Employee Benefits: | Continuation of certain employee benefits for up to 18 months | |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 85 |
Severance Payment: | A) | The sum of his or her (i) base salary at the time of termination and (ii) target bonus for the year in which his or her employment is terminated |
B) | Any annual bonus for the year prior to the year in which the termination occurs, if not yet paid | |
Employee Benefits: | Continuation of certain employee benefits for up to 12 months | |
Severance Payment: | A) | The sum of his or her (i) base salary at the time of termination and (ii) target bonus for the year in which his or her employment is terminated |
B) | A pro rata portion of his or her target bonus for the year in which the termination occurs | |
Equity: | Full vesting of all outstanding options and restricted stock unit awards (using target or earned shares, as applicable, for performance-based awards) | |
Employee Benefits: | Continuation of certain employee benefits for up to 12 months | |
86 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Severance Payment: | The sum of his (i) base salary at the time of termination and (ii) target bonus for the year in which his employment is terminated | |
Options: | Vesting of outstanding options that otherwise would have vested in the 18 months following termination | |
Restricted Stock Units: | Vesting in full of each outstanding RSU award that would have otherwise vested in the 18 months following the termination (using target or earned shares, as applicable, for performance-based awards) or, in the case of certain performance-based RSU awards, vesting of target shares pro rata over time on a daily basis from the date of grant through the date that is 18 months following the termination | |
Employee Benefits: | Continuation of certain employee benefits for up to 12 months | |
Severance Payment: | A) | The sum of his (i) base salary at the time of termination and (ii) target bonus for the year in which his employment is terminated |
B) | A pro rata portion of his target bonus for the year in which the termination occurs | |
Options: | Full vesting of all outstanding options | |
Restricted Stock Units: | Vesting in full of all outstanding RSU awards (using target or earned shares, as applicable, for performance-based awards) | |
Employee Benefits: | Continuation of certain employee benefits for up to 12 months | |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 87 |
88 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Year | Summary Compensation Table Total for CEO(1) | Compensation Actually Paid to CEO(2) | Average Summary Compensation Table Total for Non-CEO NEOs(3) | Average Compensation Actually Paid to Non-CEO NEOs(4) | Total Shareholder Return (Value of Initial Fixed $100 Investment) | Net Income (Loss)(7) | Net Product Revenue(8) | |||||||
VRTX TSR(5) | NBI TSR(6) | |||||||||||||
2025 | $ | $ | $ | $ | $ | $ | $ | $ | ||||||
2024 | $ | $ | $ | $ | $ | $ | $( | $ | ||||||
2023 | $ | $ | $ | $ | $ | $ | $ | $ | ||||||
2022 | $ | $ | $ | $ | $ | $ | $ | $ | ||||||
2021 | $ | $ | $ | $ | $ | $ | $ | $ | ||||||
Year | Summary Compensation Table Total | Amounts Deducted from Grant Date Value of Annual Equity | Amounts Added for the Fair Value of Awards Granted During Fiscal Year | Amounts Added for Awards Granted & Vested During Fiscal Year | Amounts Added/ Deducted for Awards that Vested During Fiscal Year | Amounts Added/ Deducted for the Change in Fair Value of Awards Outstanding at Fiscal Year End(a) | Compensation Actually Paid | |||||||
2025 | $ | $( | $ | $ | $ | $ | $ | |||||||
2024 | $ | $( | $ | $ | $ | $ | $ | |||||||
2023 | $ | $( | $ | $ | $ | $ | $ | |||||||
2022 | $ | $( | $ | $ | $ | $ | $ | |||||||
2021 | $ | $( | $ | $ | $( | $ | $ | |||||||
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 89 |
Year | Summary Compensation Table Total | Amounts Deducted from Grant Date Value of Annual Equity | Amounts Added for the Fair Value of Awards Granted During Fiscal Year | Amounts Added for Awards Granted & Vested During Fiscal Year | Amounts Added/ Deducted for Awards that Vested During Fiscal Year | Amounts Added/ Deducted for the Change in Fair Value of Awards Outstanding at Fiscal Year End(a) | Compensation Actually Paid | |||||||
2025 | $ | $( | $ | $ | $ | $ | $ | |||||||
2024 | $ | $( | $ | $ | $ | $ | $ | |||||||
2023 | $ | $( | $ | $ | $ | $ | $ | |||||||
2022 | $ | $( | $ | $ | $ | $ | $ | |||||||
2021 | $ | $( | $ | $ | $( | $ | $ | |||||||
90 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |


VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 91 |

Performance Measures Used to Link Executive Compensation Actually Paid to Company Performance for the Most Recently Completed Fiscal Year |
92 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
Name and Address | Shares Beneficially Owned(1) | Percentage of Total(2) |
Capital World Investors(3) | 28,739,975 | 11.3% |
333 South Hope Street, 55th Floor | ||
Los Angeles, California 90071 | ||
The Vanguard Group(4) | 22,281,729 | 8.8% |
100 Vanguard Blvd. | ||
Malvern, Pennsylvania 19355 | ||
BlackRock, Inc.(5) | 21,881,203 | 8.6% |
50 Hudson Yards | ||
New York, New York 10001 | ||
Capital Research Global Investors.(6) | 17,319,044 | 6.8% |
333 South Hope Street, 55th Fl | ||
Los Angeles, California 90071 | ||
Sangeeta N. Bhatia(7) | 4,299 | * |
Lloyd Carney(7) | 6,315 | * |
Alan Garber(7) | 37,626 | * |
Reshma Kewalramani(7) | 47,800 | * |
Michel Lagarde(7) | 6,672 | * |
Jeffrey M. Leiden(7) | 35,237 | * |
Diana McKenzie(7) | 9,429 | * |
Bruce I. Sachs(7) | 94,530 | * |
Jennifer Schneider(7) | 1,718 | * |
Nancy Thornberry(7) | 4,805 | * |
Suketu Upadhyay(7) | 5,073 | * |
Stuart A. Arbuckle(7) | 68,515 | * |
Carmen Bozic(7) | 25,497 | * |
Amit Sachdev(7) | 48,490 | * |
Nia Tatsis(7) | 38,499 | * |
Charles F. Wagner, Jr.(7) | 27,723 | * |
All directors and executive officers as a group (19 persons)(7) | 430,323 | 0.2% |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 93 |
Stock Options Exercisable Within 60 Days of March 16, 2026 | Unvested Restricted Stock Units Vesting Within 60 Days of March 16, 2026 | Deferred Stock Units as of March 16, 2026 | |
Sangeeta N. Bhatia | — | 796 | — |
Lloyd Carney | — | 796 | — |
Alan Garber | 30,754 | 398 | — |
Reshma Kewalramani | — | — | — |
Michel Lagarde | 5,540 | — | — |
Jeffrey M. Leiden | — | — | — |
Diana McKenzie | — | 796 | 6,991 |
Bruce I. Sachs | 33,965 | — | 15,565 |
Jennifer Schneider | — | 796 | — |
Nancy Thornberry | 2,770 | 398 | — |
Suketu Upadhyay | — | 796 | 2,719 |
Stuart A. Arbuckle | — | — | — |
Carmen Bozic | 5,429 | — | — |
Amit Sachdev | — | — | — |
Nia Tatsis | 8,999 | — | — |
Charles F. Wagner, Jr. | — | — | — |
All directors and executive officers as a group (19 persons) | 104,290 | 4,776 | 25,275 |
94 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 95 |
96 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
What is the Purpose of the Annual Meeting? |
What is a Proxy? |
What is a Proxy Statement? |
Why did I receive a “Notice of Internet Availability of Proxy Materials” but no proxy materials? |
What is the Difference between a Shareholder of Record and a Shareholder Who Holds Stock in Street Name? |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 97 |
How May I Attend the Annual Meeting? |
How do I Register to Attend the Virtual Annual Meeting on the Internet? |
What if I have Trouble Accessing the Virtual Annual Meeting? |
How Many Shares Must be Represented in Order to Hold the Annual Meeting? |
98 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
How Can I Vote My Shares? |
What is the Record Date and What Does it Mean? |
If I Submit a Proxy, May I Later Revoke it and/or Change my Vote? |
What if I do not Specify a Choice for a Matter when Returning a Proxy? |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | 99 |
Are My Shares Voted if I Do Not Provide a Proxy? |
What Vote is Required to Approve Each Proposal and How are Votes Counted? |
Where Can I Find More Information About My Voting Rights as a Shareholder? |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | A-1 |
A-2 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | A-3 |
A-4 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | A-5 |
A-6 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | A-7 |
A-8 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |
VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement | A-9 |
A-10 | VERTEX PHARMACEUTICALS INCORPORATED - 2026 Proxy Statement |


